Japan's Astellas to Buy U.S. Drugmaker OSI for $4 Bil.
By wchung | 01 Mar, 2026
Astellas Pharma Inc., Japan’s No. 2 drug maker, said Monday it will buy U.S. cancer drug company OSI Pharmaceuticals Inc. for $4 billion in cash in a bid to expand its cancer drug business worldwide.
Astellas said it will pay $57.50 per OSI share, up from $52 the Japanese company had offered earlier. The transaction will be completed within a month.
The acquisition is part of Astellas’ drive to expand its cancer drug business worldwide. OSI’s drugs include Tarceva, for lung cancer, which generated $1.2 billion in global sales last year.
The Japanese maker said it hopes to jointly develop cancer drugs with OSI.
Apart from cancer, OSI focuses on oncology, diabetes and obesity treatments.
TOKYO (AP)
Articles
- Iran Attack Likely to Divide Largely Isolationist MAGA Base
- Nvidia to Launch Inference-Centered Chip for OpenAI, Other AI Firms
- China Cuts Tariffs on Canadian Canola in Strategic Push to Tighten Relations
- World Reviles Lawless US-Israeli Distraction Attack on Iran
- Asian Cafes Refresh the Bay Area Coffee Scene
Asian American Success Stories
- The 130 Most Inspiring Asian Americans of All Time
- 12 Most Brilliant Asian Americans
- Greatest Asian American War Heroes
- Asian American Digital Pioneers
- New Asian American Imagemakers
- Asian American Innovators
- The 20 Most Inspiring Asian Sports Stars
- 5 Most Daring Asian Americans
- Surprising Superstars
- TV’s Hottest Asians
- 100 Greatest Asian American Entrepreneurs
- Asian American Wonder Women
- Greatest Asian American Rags-to-Riches Stories
- Notable Asian American Professionals